Based on these results, EGFR-mutated stage II lung adenocarcinoma should not be treated with conventional surgery plus adjuvant chemotherapy, but the adjuvant or neoadjuvant treatment should include TKIs. This evidence concerns the gene EGFR and lung adenocarcinoma.